HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inter Parfums Q2

This article was originally published in The Rose Sheet

Executive Summary

Global decline in consumer spending and unfavorable currency exchange rates dragged Inter Parfums' fiscal 2009 second-quarter sales down 10.6% to $88.6 mil. versus the comparable 2008 quarter, firm says July 23. Chairman and CEO Jean Madar reports that firm's Lanvin brand has "proven somewhat resilient to the economic downturn" with sales 25% higher than last year due to strength of Eclat d'Arpege, spring launch of Lanvin L'Homme Sport and reorders of Jeanne Lanvin, which debuted in the fall. Firm's specialty retail business was hurt by "especially weak" North American market, Madar says. Inter Parfums will debut new products for Brooks Brothers, Banana Republic and bebe in the second half of 2009 in domestic and international markets. "We anticipate that these new activities together with existing distribution should stem the sales decline for our U.S. operations," Madar said. European-based operations generated $79.4 mil. in sales during the second quarter, while North American operations generated $9.2 mil. For the first half of 2009, sales totaled $179 mil

You may also be interested in...

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

Generics Leaders Trade Places At The Top

In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts